- Нет данных
Русский
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
In this interview, Dr. Antonio Castelo, EPIC Biomedical and Laser Technology Manager, had a conversation with Aldas Juronis, CEO of EKSPLA, a Lithuanian innovative solid-state and fiber laser manufacturer.What is the background of your appointment as the CEO of EKSPLA?In 1994, I graduated from Kaonas University of Technology in Lithuania with a Bachelor's degree in Radio Electronic Engineering. At...
A team of researchers in Berkeley Lab's Accelerator Technology and Applied Physics (ATAP) division has developed a new technique that combines fiber lasers of different wavelengths to generate ultra-short laser pulses. The research is in the journal Optics Letters.This work could advance the development of laser plasma accelerators (LPA), which have the potential to push the frontiers of high-en...
Organic solid-state lasers (OSLs) are expected to achieve widespread applications due to their flexibility, tunability, and efficiency. However, they are difficult to manufacture and require over 150.000 possible experiments to find successful new materials, and discovering them will be a work of several lifetimes. In fact, according to data from the University of Toronto in Canada, only 10-20 new...
A sketch of the imaging and holographic parts of a transient holographic microscope, including a pulse sequence, to illustrate the signal modulation method. By imaging the pinhole array at the sample position, a diffraction limited excitation spot array can be created, allowing for the simultaneous collection of transient data around 100 excitation spots.Femtosecond transient microscopy is an impo...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...